promote sensory axon growth after CNS injury remains to be fully elucidated.
Some questions remain. Is regeneration suppressed by active synaptic transmission or the mere formation of synapses? If it is the synaptic activity, how are neuronal excitability, electrical activity, and synaptic transmission related in regulating axon growth? The in vivo role of alpha2delta2, as opposed to alpha2delta1/3, remains to be fully tested with spinal cord injury models, and the extent of axon regeneration may still be limited with Pregabalin administration alone. It will be important to determine whether Pregabalin treatment could synergize with a number of other molecular manipulations to promote significantly more axon regeneration and whether any enhanced axon growth would translate to behavioral improvement. It will also be critical to determine whether the role of alpha2delta2 extends to axonal tracts other than dorsal column sensory axons. Finally, the exact mechanism underlying how alpha2delta2 deletion or pharmacological manipulation promotes axon growth remains elusive. The known roles of the alpha2delta2 subunit in mediating active zone VGCC density and vesicular release probability suggest that vesicular release may be involved in the process, a hypothesis that has yet to be tested. Regardless, the demonstrated in vivo effect of Pregabalin on regeneration is an important finding, especially considering the use of Pregabalin in spinal cord injury patients to treat neuropathic pain.
In summary, Tedeschi et al. (2016) put forth the first candidate molecular player in a hypothesis of regeneration failure that will likely evolve into a fundamental principle for axon regeneration after CNS injury: that regeneration is suppressed by target innervation, synapse formation, or transmission. While this notion may sound straightforward, the mechanistic details are just beginning to be revealed.
In this issue of Neuron, Younts et al. (2016) demonstrate that activation of presynaptic CB1 receptors by retrograde endocannabinoid signaling stimulates protein synthesis in axon terminals to induce long-term depression of hippocampal inhibitory transmission.
Synaptic plasticity is a critical process that regulates the strength of synaptic transmission over timescales ranging from seconds to days and longer. Forms of long-term potentiation (LTP) and longterm depression (LTD) have been identified in several species, across many brain circuits, and at both excitatory and inhibitory synapses within the same brain regions. Discoveries indicating that diverse forms of synaptic plasticity are disrupted in a staggering array of CNS disorders, including Alzheimer's disease, fragile X syndrome, and drug addiction, underscore the necessity of elucidating the mechanisms that normally regulate LTP and LTD. Long-term changes in synaptic strength can be induced by particular patterns of afferent activity and by activation of G protein-coupled receptors, such as cannabinoid type 1 (CB1) receptors or metabotropic glutamate receptors. Plasticity can occur postsynaptically, often corresponding to changes in surface expression or function of ionotropic neurotransmitter receptors, or presynaptically, associated with long-term changes in the probability of neurotransmitter release. While some forms of synaptic plasticity are well characterized, many of the molecular mechanisms contributing to presynaptic forms of LTP and LTD remain poorly understood.
Long-term decreases in neurotransmitter release mediated by retrograde endocannabinoid (eCB) signaling (eCB-LTD) represent a prominent form of presynaptically expressed LTD in the CNS (for review, see Atwood et al., 2014; Castillo, 2012) . eCB-LTD has been identified in many brain regions, including the hippocampus, striatum, nucleus accumbens, and amygdala. Several molecular mechanisms, including signaling pathways leading to postsynaptic eCB synthesis and presynaptic roles for PKA, Rim1a, and voltage-dependent calcium channels, have been identified. However, many questions remain regarding the process by which CB1 receptor activation produces a long-term decrease in neurotransmitter release probability. Interestingly, protein synthesis has long been recognized as a critical contributor to postsynaptic forms of plasticity (Santini et al., 2014; Schuman et al., 2006) and thus has been postulated as a candidate mechanism for presynaptic forms of plasticity as well. Importantly, it is relatively straightforward to experimentally assess the involvement of postsynaptic events using standard whole-cell patch-clamp techniques, as pharmacological inhibitors of the processes of interest can be included in the internal recording solution. In contrast, evidence for the involvement of protein synthesis in presynaptic forms of LTD in the mammalian CNS has been much less direct due to the inherent difficulty of specifically manipulating presynaptic processes.
In this issue of Neuron, Younts and coworkers provide compelling evidence that presynaptic protein translation is a key process in LTD at inhibitory synapses in the hippocampus (iLTD) (Younts et al., 2016) . Using standard slice electrophysiology techniques, they find that bath application of the protein synthesis inhibitors anisomycin and cycloheximide prevents iLTD induction, but this effect is not mimicked by postsynaptic loading of synthesis inhibitors in the recorded neuron. From this experimental procedure, a role for presynaptic protein synthesis can be inferred, but direct evidence remains lacking. Because local inhibitory microcircuits remain intact in the hippocampal slice preparation, the inhibitory synapses evaluated in this study provide an ideal system for evaluating the contribution of presynaptic processes to plasticity. Preservation of microcircuits permits an elegant paired recording approach in which whole-cell patch clamp of a presynaptic, CB1-expressing interneuron and a connected postsynaptic CA1 pyramidal neuron can be performed simultaneously ( Figure 1A ). Presynaptically evoked action potentials trigger GABA release, and the resulting unitary inhibitory postsynaptic current (uIPSC) is recorded from the postsynaptic neuron; changes in synaptic strength in response to LTD induction protocols can then be monitored. Importantly, access to the intracellular space of the presynaptic neuron allows pharmacological manipulation of cellular processes, providing a direct method to interrogate the roles of presynaptic signaling and protein synthesis. Employing this technique, Younts et al. (2016) find that loading the presynaptic cell with M7, a membrane-impermeable inhibitor of cap-dependent protein synthesis, impairs induction of iLTD, but postsynaptic loading has no effect ( Figure 1A) . Moreover, loading the presynaptic neuron with gelonin, a relatively large ribosome-inactivating toxin that is unlikely to diffuse to distal axon terminals, fails to disrupt iLTD. This finding supports the notion that axonal, rather than somatic, protein synthesis is required for iLTD. Notably, blocking protein synthesis does not alter the strength of basal synaptic transmission. Furthermore, a form of short-term depression mediated by CB1 receptors at the same synapses (depolarization-induced suppression of inhibition, or DSI) is insensitive to protein synthesis inhibitors. Collectively, these findings suggest that constitutive protein synthesis in both pre-and postsynaptic elements is not needed for acute modulation of synaptic transmission and that the requirement for CB1-dependent protein synthesis is specific to long-term changes in the probability of neurotransmitter release.
The finding that iLTD is dependent on protein synthesis suggests a direct role for CB1 in promoting translation. To test this hypothesis, Younts et al. (2016) measured new protein synthesis in primary hippocampal neuron cultures and report that a CB1 agonist increases translation in both soma and axons. This is the first report of CB1 activation stimulating protein translation. In heterologous expression systems, CB1 has been shown to engage p38 mitogen-activated protein (MAP) kinase, extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin (mTOR) signaling pathways, all of which could play a role in CB1-mediated protein synthesis. Younts et al. (2016) demonstrate that the CB1-mediated increase in protein synthesis in cultured neurons is prevented by pharmacological inhibition of mTOR. Consonant with this finding, inhibition of mTOR in hippocampal slices abolishes LTD induction ( Figure 1B) . These results fill in critical gaps in our knowledge of the processes involved in CB1-dependent, long-term regulation of neurotransmitter release.
Although some earlier studies indicated that presynaptic protein translation has a prominent role in eCB-LTD (Kellogg et al., 2009; Yin et al., 2006; Yuan and Burrell, 2013) , the evidence largely rested on pharmacological or anatomical approaches that could be applied in the preparations/synapses examined or were not performed in mammalian systems. The use of paired recordings by Younts et al. (2016) provides the first direct evaluation of the requirement for protein synthesis in the mammalian brain. However, it must be noted that one previous study indicated that the protein translation inhibitor anisomycin did not disrupt eCB-LTD at glutamatergic synapses in the nucleus accumbens (Jung et al., 2012) . Anisomycin inhibition of protein production in brain slices was not examined by Jung et al. (2012) , and thus it is not clear whether this pharmacological approach was effective. In addition, Younts et al. (2016) find that blockade of protein synthesis immediately following iLTD induction does not disrupt LTD, whereas in the striatum, high-frequency stimulation-induced eCB-LTD at excitatory synapses is prevented when protein synthesis is blocked after LTD induction (Yin et al., 2006) . Interestingly, a study in leech synapses found that both pre-and postsynaptic protein translation were necessary for eCB-LTD (Yuan and Burrell, 2013) . The reasons for these apparent discrepancies are not clear, but it is possible that CB1 activation induces LTD in different circuits and at excitatory versus inhibitory synapses via different mechanisms. Further, LTD induction protocols vary widely between synapses and research groups, which could also account for inconsistent observations.
A critical element lacking in previous assessments of presynaptic protein synthesis roles in eCB-dependent LTD was anatomical evidence for the presence of the required translation machinery. Older studies that failed to observe ribosomes in mature mammalian axons, combined with knowledge that somatically synthesized proteins can be trafficked to distal neuronal compartments, contributed to the dominant belief that presynaptic protein synthesis does not occur. However, it is now widely accepted that ribosomes can be found in axonal growth cones during early development (Holt and Schuman, 2013) . Still, there is little evidence that ribosomes are present in mature mammalian axon terminals. Components of translation machinery were recently identified in synaptosomes prepared from adult rat brains (Wilhelm et al., 2014) , lending support to the idea that presynaptic translation occurs in mature terminals. Yet, previous attempts to image ribosomes in mature mammalian axon terminals were not fruitful. Younts et al. (2016) used the newly developed, super-resolution stochastic optical reconstruction microscopy (STORM) imaging technology to provide evidence that ribosomomal proteins are present in presynaptic terminals. The current study demonstrates that ribosomes are abundant in close proximity to the presynaptic plasma membrane of axon terminals belonging to CB1-expressing interneurons and are therefore well poised to mediate a local response to CB1 activation. This finding (B) Multiple depolarizing voltage steps in the postsynaptic neuron cause endocannabinoid (eCB) production. eCBs are retrogradely transported to bind to presynaptic CB1 receptors. CB1 activates mTOR to promote cap-dependent translation of unidentified proteins that act as a molecular switch to yield a longterm reduction in the probability of GABA release. is likely to stimulate renewed interest in the possibility of presynaptic protein translation in axon terminals of glutamatergic neurons and additional classes of interneurons as well.
That protein synthesis in axon terminals is possible and represents a key process contributing to presynaptic iLTD is an intriguing concept, as it provides a clear mechanism for a subset of a neuron's synaptic connections to independently respond to their unique environments. However, critical unanswered questions arise as well. What proteins are translated in these GABAergic presynaptic terminals, and how do they serve as a molecular switch linking CB1 activation to a long-lasting decrease in neurotransmitter release probability? Some clues may be found in earlier studies from the Castillo group and others concerning the molecules involved in eCB-LTD. Intraterminal signaling involving cyclic AMP (cAMP) has been implicated in presynaptic LTD at several synapses, and thus proteins that are part of this signaling system (e.g., adenylyl cyclase and PKA) may be produced in the LTD process (Atwood et al., 2014) . The vesicle-associated protein Rim1a also appears to have a key role in eCB-LTD, as shown by the Castillo group and others (Chevaleyre et al., 2007) , and this protein, or proteins that regulate Rim1a, may also be locally produced (Castillo, 2012) . Other possibilities include proteins involved in vesicle fusion, structural proteins that influence the function of the axon terminal, and proteins that modulate the function of other players in neurotransmitter release, such as voltage-gated calcium channels. Identification of RNA species present in the terminals will provide valuable information about the mechanistic possibilities brought into play by presynaptic translation. Furthermore, employing proteomics approaches to identify presynaptic proteins that show altered expression levels after prolonged CB1 activation could expose novel participants in the long-term regulation of neurotransmitter release. The finding that presynaptic protein synthesis is required for eCB-LTD provides an intriguing foundation for further elucidation of the specific mechanisms governing synaptic plasticity.
